Long-term efficacy of treating sPTRCT with injection of either UA-ADRCs or corticosteroid
Pain, pain
Four of the 11 subjects (36.4%) in the UA-ADRCs group and three of the five subjects (60.0%) in the corticosteroid group developed additional pathologies of the index shoulder (next to sPTRCT) and/or received additional injections into or surgery of the index shoulder (next to injection of either UA-ADRCs or corticosteroid) during the present and the former studiesThe individual ASES Total scores, SF-36 Total scores and VAS pain scores as a function of time post-treatment are shown in Supplementary Figs. Statistical analysis demonstrated that compared with the subjects in the corticosteroid group, the subjects in the UA-ADRCs group had (i) a significantly higher mean ASES Total score at W24 and W52 post-treatment as well as at SSV (i.e., at 40.6 ± 1.9 months post-treatment), (ii) a significantly higher mean SF-36 Total score at W24 post-treatment, and (iii) a significantly higher mean VAS Pain score at W24 and W52 post-treatment (Fig. Tukey boxplots of (Tukey boxplots of (